<SEC-DOCUMENT>0001193125-22-176610.txt : 20220617
<SEC-HEADER>0001193125-22-176610.hdr.sgml : 20220617
<ACCEPTANCE-DATETIME>20220617165457
ACCESSION NUMBER:		0001193125-22-176610
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20220617
FILED AS OF DATE:		20220617
DATE AS OF CHANGE:		20220617

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAZIA THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		221024701

	BUSINESS ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVOGEN LTD
		DATE OF NAME CHANGE:	19981228
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d713471d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR
<FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of June, 2022 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number <FONT STYLE="white-space:nowrap">000-29962</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Three
International Towers Level&nbsp;24 300 Barangaroo Avenue Sydney NSW 2000 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT
STYLE="white-space:nowrap">40-F.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form <FONT STYLE="white-space:nowrap">40-F&nbsp;&nbsp;&#9744;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT
STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION CONTAINED IN THIS FORM <FONT STYLE="white-space:nowrap">6-K</FONT> REPORT </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;17, 2022, Kazia Therapeutics Limited (the &#147;Company&#148;) issued a press
release titled, &#147;US FDA Awards Orphan Drug Designation (ODD) to Paxalisib for AT/RT, a Rare Form of Childhood Brain Cancer.&#148; A copy of this press release is attached hereto as Exhibit&nbsp;99.1 and is incorporated herein by reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby incorporates by reference the information contained herein into the Company&#146;s registration statement on <FONT
STYLE="white-space:nowrap">Form&nbsp;F-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-259224).</FONT> </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT LIST
</U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d713471dex991.htm">Press Release of Kazia Therapeutics Limited dated June&nbsp;17, 2022 </A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Kazia Therapeutics Limited</B> (Registrant) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>/s/ Karen Krumeich </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Karen Krumeich </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Financial Officer </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: 17&nbsp;June 2022 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d713471dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>&nbsp;&nbsp;&nbsp;&nbsp; </B></P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713471dsp03.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX RELEASE </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">17&nbsp;June
2022 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>US FDA AWARDS ORPHAN DRUG DESIGNATION (ODD) TO PAXALISIB </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR AT/RT, A RARE FORM OF CHILDHOOD BRAIN CANCER</B><B><I> </I></B><B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sydney, 17</B><B></B><B>&nbsp;June 2022</B> &#150; Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is
pleased to announce that the United States Food and Drug Administration (FDA) has awarded Orphan Drug Designation (ODD) to Kazia&#146;s paxalisib for the treatment of atypical rhabdoid / teratoid tumors (AT/RT), a rare and highly-aggressive
childhood brain cancer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Key Points </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Orphan Drug Designation (ODD) is a special status accorded to drugs which are considered promising potential
treatments for rare (&#145;orphan&#146;) diseases, generally defined as those which affect less than 200,000 cases per annum in the United States. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">ODD can provide drug developers with up to seven years of Orphan Drug Exclusivity (ODE), during which
competitors may not rely on Kazia&#146;s data to develop generic versions of paxalisib, effectively extending the effective life of a commercial product. It also provides opportunities for grant funding and protocol assistance, and tax credits.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">FDA will waive fees relating to a future regulatory filing in AT/RT, potentially saving more than
US$3&nbsp;million if Kazia seeks approval in this indication. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Paxalisib has previously been granted ODD in malignant glioma, a category of brain cancer that includes both
glioblastoma, an adult brain cancer which is the lead indication for the drug, and diffuse intrinsic pontine glioma (DIPG), a rare childhood brain cancer which is currently the subject of a phase II study led by the Pacific Pediatric Neuro-Oncology
Consortium. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia CEO, Dr James Garner, commented, &#147;childhood brain cancer has emerged as an important area of focus for the
paxalisib program. We have been working for some years with several world-leading researchers in DIPG, one of the most aggressive childhood cancers. Recent data presented at the AACR conference by Dr Jeffery Rubens and colleagues from Johns Hopkins
Medical School has shown the potential of the drug to also add benefit in AT/RT, another form of childhood brain cancer that is very poorly served by existing treatments. This represents an important new opportunity for paxalisib, and one that we
continue to explore enthusiastically with our collaborators and advisors.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mr Iain Ross </B>Chairman,<B> </B><FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director<B> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mr Bryce Carmine </B><FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director<B> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mr Steven Coffey </B><FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director<B> </B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dr James Garner </B>Chief Executive Officer, Managing Director </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Three International Towers, Level&nbsp;24, 300 Barangaroo Avenue, Sydney NSW 2000 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Orphan Drug Designation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ODD exists to recognise and encourage the development of a drug for a rare disease, which may affect adults or children. ODD provides an additional period of
7.5 years data exclusivity (for a paediatric disease), which allows companies to better defend their products against competition. It also results in a waiver by FDA of fees for a marketing application, under the Prescription Drug User Fees Act
(PDUFA fees), which are over US$ 3&nbsp;million in FY2022. In addition, drugs with ODD may be eligible for orphan grants by FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia previously
received ODD for paxalisib in glioblastoma in February 2018, and for malignant glioma in August 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Next Steps </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A phase II clinical trial of multiple drug therapies, including paxalisib, is ongoing, under the sponsorship of the Pacific Pediatric Neuro-Oncology Consortium
(PNOC) (NCT05009992). This study combines several investigational drugs in the treatment of patients with diffuse midline gliomas (DMGs), a category which includes DIPG. Initial data from this study is anticipated in CY2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A phase I study of paxalisib in DIPG, led by St Jude Children&#146;s Research Hospital in Memphis, TN (NCT03696355), is nearing completion, and final data is
expected to be submitted for publication by the end of CY2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia Therapeutics will participate in a webinar to discuss the company&#146;s activities
in childhood brain cancer on Wednesday 22nd June 2022. Registration details are available via the company website. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For More Information, Please
Contact:- </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I><U>In the United States:</U></I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I><U>In Australia:</U></I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Joe Green</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Jane Lowe</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Edison Investor Relations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">IR Department</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>jgreen@edisongroup.com</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>jane.lowe@irdepartment.com.au</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Phone: +1 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">646-653-7030</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Phone: +61 411 117 774</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Kazia Therapeutics Limited </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) is an oncology-focused drug development company, based in Sydney, Australia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead program is paxalisib, a brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat glioblastoma, the most common
and most aggressive form of primary brain cancer in adults. Licensed from Genentech in late 2016, paxalisib commenced recruitment to GBM AGILE, a pivotal study in glioblastoma, in January 2021. Seven additional studies are active in various forms of
brain cancer. Paxalisib was granted Orphan Drug Designation for glioblastoma by the US FDA in February 2018, and Fast Track Designation for glioblastoma by the US FDA in August 2020. In addition, paxalisib was granted Rare Pediatric Disease
Designation and Orphan Designation by the US FDA for DIPG in August 2020, and Orphan Designation for AT/RT in June 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia is also developing EVT801,
a small-molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to be active against a broad range of tumour types and has provided compelling evidence of synergy with immuno-oncology agents.
A phase I study commenced recruitment in November 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information, please visit <U>www.kaziatherapeutics.com</U> or follow us on Twitter
@KaziaTx. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This document was authorized for release to the ASX by James Garner, Chief Executive Officer, Managing Director. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g713471dsp03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713471dsp03.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@!55F.%4GZ"@+V-
M'2=$N=7:3R61$CZL_KZ5I3IN>QSUL1&C:XZVT&\N-4EL/D22$9=B> .WYYIJ
ME)RY0GB81IJIT96U#3I]-O#:S %\ @KR&'M43@X.S+I58U8\R*A!4X((([&I
M-0H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M2'/F2E%7GZEC^%2Y/E12BN9G WMI)87]Q9RC$D$C1M]0<'^5:+4S:L04Q!0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % %K3]-N=3G,5L@9E&22< "JA!S
M=D9U*L:2O(W]$O8/#TMU::BABFR#N W9&.G%=%*2I-J1PXBG+$J,Z>J,Z/7Y
MK+4KNXL4589VSY;CCZ\=#6:JN,FXG0\,IPC&>Z(H-7U"UOWU$<O-PQ=?E;V_
M2LXUFIMIZFT\(G22<6H]&6M.UT'7_M^H\Y0J"J\)Z8'Y_G6L*OO\TCGJX?\
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M9XHHI;AMSK$"%SCDC)/7KUJDK*Q+=W<I4Q!0 4 % !0 4 % !0 4 % !0 4
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH 6-7>15C!+D@*!U)H7D)M)79T>MZMJIL%L[VT$'F8R_]_'^1714J3Y>62.'
M#T**GSP=[%'3;R;3[220VK/"QR'Z<]*\C$4HUII*5F?6Y?BZN"HRFZ;<7U,]
M(Y+Z]"1H#),_ '3)-=T(62BCPZU5-RJ2TW9T,W@NXCMB\5TLDP&=FW /L#FN
MIX9I:,\R./BY6:T,"RN397:S;-VW(*GBN"M2]K!P/<P>)^JUE5M>Q8U:6:YF
M2=[=H4*X7=WK+"QC3BX*5V=>9U*M><:LX.*M9&LNJ:SJ6AO!#9AXU78\JCD@
M>WK7J<]2<+)'S/L:%*KS.6O8YFN8] Z/P#_R/>C_ /7<?R-1/X67#XD>\ZUX
MFMM"UK2;*\PD.H&1!*3PCKMVY]CN(_*N=1NF;N5F>>?%KP>ZR/XEM&=U;:MR
MA.=O& P]N@(K6G+H9U(]3R:MC$='&\LBQQJ6=B%50.23VH ^C[31[WPUX!&G
M:- )M12'"C<%S*WWFR>."2?P KENG*[.I+EC9":'I.H7W@,:+XB@,4_E-;L?
M,5R5Q\K9!/(&/Q%#:4KH$GRV9\\ZGI\^DZI<Z?<C$UO(8V]\=Q['K72G=7.9
MJSL5:8CV_P"$GAM--T237;D 3W@(C+<;(@>OXD9^@%<]25W8WIQLKGF7CCQ&
M?$WB>XO%/^C1_NK<?[ /7\3D_C6L(\J,Y.[.=JR#N/A+_P CY!_UQD_E6=3X
M32G\1H?&G_D:K'_KS'_H;TJ6PZFYYO6ID>Q?!SPYY=M/X@G7YI<PV^>R@_,W
MYC'X&L*LNAO374ZK2SXG'CG49KVQV:-.@CA;SD.S9G:V <_-DY^H]*A\O+H4
MKW/-?BUX=&E^(5U2!<6^H99@/X9!][\^#]<UK3E=6,ZBL[GGM:F04 % !0 4
M % !0 4 % !0!UM]+#>>%+2SMIDCN;>W6:9=P'GH"0!GU3D[>X8GM4+1EO56
M+DFFV0NM/2W-@72>17DVQE&B"*=P7<=V?F*[CDD]NRNQV14MH+*X:69[>UMY
MOM<["%@IPNP%5 ) .">,\<=#T)J@5C+U6*UMO%92TV"W$D;#8P*C(4GD<=2:
MI;$O1EPWD=O>^)Y5\F4L^8Q( RM^_!Z=^*5MAWM<MSV>BQZ9J7E>46CGN5 R
MA( (\K#%LXZ] <\YZ<*[N.RL/MH--FUZ1/+L5MX8H%"X7YMVS>V68#/7)Y(S
MP.X-; K7*JV=E'H$KO%;B+%P!*2/,WJR^6!SD_AV)].'=W%;0O26>B"6R11;
ME'8K&S&-05,)QG#$GY\?,P&#D?178[(I8BM-&O[6,6HF:PB9A\C$L)/FP?7'
M8<\>U/J+9"WEO91RZC]CAL7C$THD\QU&R/RQL*<Y^]NZ=2 .^*%<-.A5UF"T
M70K26!;6-CY8*J5+_<^8AE.2">H8 J2 .,T+<':Q;O;)9-6T^]F\A[)[&W3<
M95/S"U48(SD8*GJ.HH3TL#6I<L$T<C3HI;>R(>>QBE9@,[)%?SB3G_97GM[9
MI.XU8S86@BT(QVZVWFS:26DW*A8N+MNYY#;!VYP >PI]1="Y-::.J6/DB!V/
M,6\HH8^3D!L-DCS,9+8ZD?1:CLC'\2ONDTT'R0ZV:JZPD%5;<V1QP/I51)D8
ME42% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!8L;HV-]#<A0WEL#@]ZJ,N
M5ID5(<\''N;'B+5WU."W*V<L, )(>0?>/M6M6ISI:')A:"I-ZW97@O;FYTMK
M.&U+E5VEP>,?XUY$Z,*=;VDI6/KZ.+KXC"/#4J=[*U_+_,IZ7=C3M4@N74D1
MM\P[XZ&O2IRY9*1\U6IN<'#J=S+XFTJ.W\U;G><<(H.X_P"%=SK02O<\6.$J
MN5K'GX$EU='RTS([$A1^=>;.2BG*6Q]#1I3G)0IJ[-'5K^XDB6UGM_*<89N<
MY^E<6%H0B_:0E<]O,\=6J05"K#E>[_X!H:5KT^EZ*$>PD>,$^7+@A3GU/UKV
M(57"&Q\C6PT:M6ZE\CFF8LQ8]2<US'H+0VO!U[;Z=XOTR[NY1%;Q3 NYZ*,5
M,E=%1=F=A\6O$.DZZ-(&F7T=R8?-\S9GY<[,?R-13BU>Y=1I[&[X*^(^EW/A
M_P#LWQ)<I'-"OE[Y5++/'C'/'7L<]?SJ90:=T5&:M9GE_BBTTJSUZ=-%O%N;
M!OGC(S\F?X>?3^6*UC>VIE))/0U?AVVCV_B=+_6;R*WAM%\R,29^>3H/RZ_4
M"E.]K(<+7NSL/%GQ:FM-6$'AUK:XM40;Y9(V.YO;D< 8_6LXT]-2Y5+/0J^'
M_B]J,VMVT6M"UCL')622.-@4XX/4\9Q3=-6T!5'?4ROBE>:)JNK6NIZ1?0W$
MDD9CG6/.<K]UCQZ''X"G332LR:EF[HXW2;>UNM6M8+ZY%M:/(!+*?X5[UH]%
MH0MSZ"'C/P6MB+$:I:?91'Y7E8.W9C&W&.F*YN61T\T3"U&^^&ITR[$":3YQ
MA?9MMP#NP<8XZYJDIW);@>'5T'.=;\-]4LM(\80W>H7"V\ B=2[= 2.*B:;6
MA<&D]2[\5-9T[6_$5I/IMTES$EJ$9DS@'>QQ^HI4TTM1U&F]#AXD$DR1LZQA
MF +-T7W-:&9[?J7CS0O#/@^&S\/7L%W=P(D4*;21QU9NGO\ B:YU!R>IT.2B
MM#CO^%Q>)O\ GE8_]^6_^*J_91,_:,ZCQ1XG\,^+O C1RZC#!J'EB:.)P<I*
M!RO3OR/QJ8QE&1<I*43Q>MS * "@ H * "@ H * "@ H D-O,+87)A<0%R@D
MVG:6 SC/3.".*0RS+H^J6[P)-IMU&\[!8E>%@9">@7(Y/(Z>M%T%F57@FC3<
M\3HNXIEE(&X8R/J,C(]Q3$3)IU])-Y,=E<-+MW[%B8MM]<8Z>]*Z'9D:VUP[
M2*D$C-$"7 4G8!USZ4 'V:XV1/Y$FV4XC.TX<^@]: L'V6X^T_9O(D\_./+V
M'=GTQUH"Q+Y%_-8[A!.]K;DC<$)1"<9R>W:C0-2/[%=?:$M_LTOG.,K'L.YA
M[#O1<+$G]EZAOE3[!<[H0#(/*;* ]">.*+H+,KF-Q&LA1@C$@-C@D8R,_B/S
MIB&T % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 #@T =
M;J.N0ZQI7V*SM)7N'QE F=F#VQ77.JIQY8K4\REAY4*G/-Z&'9ZA/I1E@>#Y
ML\J^05->7B,*JK5W9H^FP&9RPD6HI-,?-I4C6!OVE4NP\PKCC!]ZRAB8JI[)
M+1:'36RV<L.\6Y:O6WJ4Y+"YBMA</$1$>]=$:U.4N1/4\Z>"Q%.DJTH^Z:1L
M9-(BBODE5V7&Y2..?>N15EB6Z35CV'@IY;".+C*[6Z]2G<2W.L78,5NS,%P$
M0$X%=>'H>RCRQU/'Q^/^LS]I.RMH;EYXB@.AMI[6LB7.P1,C+@+CO7H2K+DY
M;:GA4\+)5?:)Z;G*URGI  2< <T *48'!4@_2@+B8/'!YZ4 *48$ J0?3% 7
M0A!4X((/O0  $G '/I0 NUMVW!SZ8H "K D%2"/:@ "L3@*2?I0%Q"I&<@C'
M6@ VG;NP<=,T !4@ D$ ]#0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M =1OTT^&WTLWQ^T"W6X";5\KS02WW]WWMCE<8ZC%1K>Y>EK&M=W%E'K]M<+/
M:I&^JV\Q=+M)-ZC.7(!^0#/?'7VJ5>Q6ES"UBXM[C1M+GAN(_.FN)IIHPV6C
M<K$"2.P)5F'L?:J6C)>R+<LB#5],:ZU&&5[?S))G6<.) K&3.[U<Y 7KTXR:
M.@^I#X8O42[\^YN43;?V]S,9) A>-=_F=?O?>' Y.>E$D*++=S/#/:6C6E_%
M:2E+5(V^T_Q+ 5<LN?DPV0"0/O$\@\(95?%SXF@6.]BMU^RJDK"Y3"JL>"@D
M)P20,9SU-/9"ZCVODN[747OUM%87,]P"EP"PE;80H4'#(2,9YXST[EK;!?N1
M:_+!<R:?##-$L[2RL[BY$BJ'?(^< 8'4X/(SS1'0&6QJ-K>7>JVSO"=.,T2A
MWF*2".*.1%91D;C@@D<\D<'LK6L.^YF:M<6$OAS2H;2X=G@9PT31@$$JA8YR
M<_-G!QT^E4KW)=K(PJHD* "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M# L!M 48 %93FYN[.FE2C2CRQ*M2:!0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
K4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
